Helper roles of NK and CD8+ T cells in the induction of tumor immunity -: Polarized dendritic cells as cancer vaccines

被引:51
作者
Kalinski, Pawel
Nakamura, Yutaro
Watchmaker, Payal
Giermasz, Adam
Muthuswamy, Ravikumar
Mailliard, Robbie B.
机构
[1] Univ Pittsburgh, Dept Surg, Inst Canc, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA
关键词
dendric cells; cancer; immunotherapy; vaccines; Th1; CTL; NK cells; clinical trials; melanoma; colorectal cancer; prostate cancer;
D O I
10.1385/IR:36:1:137
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8(+) and CD4(+) T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8(+) T cells and NK cells, the classical "effector" cells, also play "helper" roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8(+) T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.
引用
收藏
页码:137 / 146
页数:10
相关论文
共 71 条
[1]   Migration of dendritic cell based cancer vaccines:: in vivo veritas? [J].
Adema, GJ ;
de Vries, IJM ;
Punt, CJA ;
Figdor, CG .
CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (02) :170-174
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]   Dendritic cells as therapeutic vaccines against cancer [J].
Banchereau, J ;
Palucka, AK .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :296-306
[4]   Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs [J].
Calzascia, T ;
Masson, F ;
Di Berardino-Besson, W ;
Contassot, E ;
Wilmotte, R ;
Aurrand-Lions, M ;
Rüegg, C ;
Dietrich, PY ;
Walker, PR .
IMMUNITY, 2005, 22 (02) :175-184
[5]   CD56(bright) natural killer cell subsets: Characterization of distinct functional responses to interleukin-2 and the c-kit ligand [J].
Carson, WE ;
Fehniger, TA ;
Caligiuri, MA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (02) :354-360
[6]   Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity [J].
Chan, CW ;
Crafton, E ;
Fan, HN ;
Flook, J ;
Yoshimura, K ;
Skarica, M ;
Brockstedt, D ;
Dubensky, TW ;
Stins, MF ;
Lanier, LL ;
Pardoll, DM ;
Housseau, F .
NATURE MEDICINE, 2006, 12 (02) :207-213
[7]   Human natural killer cells:: a unique innate immunoregulatory role for the CD56bright subset [J].
Cooper, MA ;
Fehniger, TA ;
Turner, SC ;
Chen, KS ;
Ghaheri, BA ;
Ghayur, T ;
Carson, WE ;
Caligiuri, MA .
BLOOD, 2001, 97 (10) :3146-3151
[8]  
Czerniecki BJ, 2001, CRIT REV IMMUNOL, V21, P157
[9]  
de Vries IJM, 2003, CANCER RES, V63, P12
[10]  
de Vries IJM, 2003, CLIN CANCER RES, V9, P5091